Freestone Grove Partners LP Cogent Biosciences, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 32,193 shares of COGT stock, worth $260,441. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,193Holding current value
$260,441% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
190Shares Held
104MCall Options Held
157KPut Options Held
439K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$73.7 Million4.5% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$59 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$56.3 Million8.87% of portfolio
-
Commodore Capital LP New York, NY6.88MShares$55.7 Million5.38% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$50.4 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $532M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...